Several clinical studies of MNPR-201 have been completed. A Phase 1 dose escalation study conducted at the University of Iowa enrolled 24 patients at 5 different dose levels of MNPR-201 ranging from 14-265 mg/m2. No evidence of irreversible cardiotoxicity was observed in any of these patients, including 4 patients that had received prior anthracycline (doxorubicin or related molecules) treatment. In the four highest dose levels (>84 mg/m2), 9/17 patients showed a stabilization of disease including 3 out of 4 patients with leiomyosarcoma, which is a type of cancer that originates in connective tissue and smooth muscle most commonly in the uterus, stomach and small intestine.

Based on the demonstration of stable disease in patients with leiomyosarcoma in the Phase I trial, a multi-center open label single arm Phase 2 trial was run in doxorubicin-naïve patients with non-resectable or metastatic soft tissue sarcoma (STS). Doxorubicin has historically been the standard of care for the treatment of leiomyosarcoma and other STS. This Phase 2 clinical trial enrolled 22 patients and was completed in early 2017. MNPR-201 was administered intravenously at 265 mg/m2 every 3 weeks for up to 16 doses and there was clear indication of anticancer activity and no evidence of irreversible cardiotoxicity. One patient went on compassionate use and received 20 cycles of MNPR-201, many more than the 6 to 8 cycles patients on doxorubicin are typically limited to. The progression free survival at 6 months was 38%, versus doxorubicin’s 6-month progression free survival of 25%, 33%, and 23% in three separate studies in this patient population (Lorigan et al., 2007; Judson et al., 2014; Chawla et al., 2015).

Development Strategy

Learn more about the next stage of clinical development for MNPR-201.

Development Strategy